Coupang Unveils Rebranding of AI Cloud Computing Service
CIC's data centers, located in Seoul, South Korea and the greater metropolitan area, are equipped with cutting-edge infrastructure. These facilities feature high-capacity power systems, advanced cooling technologies, redundant power architecture, multi-network support, and robust physical security—helping to ensure stable operations.
About Coupang
Coupang is a technology and Fortune 150 company listed on the New York Stock Exchange (NYSE: CPNG) that provides retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, Farfetch, and Rocket Now.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250701062661/en/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 minutes ago
- Globe and Mail
10 Incredible Growth Stocks Poised for Long-Term Gains
Growth stocks have been on a tumultuous ride in 2025. The confluence of geopolitical turmoil, high interest rates, the artificial intelligence (AI) superbuild, and valuation concerns has created dramatic volatility. While everyone obsesses over the " Magnificent Seven," a collection of transformative companies are quietly hitting key inflection points -- and some may offer truly compelling opportunities at current valuations. Here are 10 growth stocks that deserve serious consideration right now. The insurtech disrupting healthcare Oscar Health (NYSE: OSCR) just posted 42% revenue growth to $3 billion in Q1 2025, with membership surpassing 2 million. The company's tech-first approach to health insurance is finally hitting scale, with net income jumping to $275 million from $177 million year over year. At just 15.4 times 2027 projected earnings, Oscar trades like a mature insurer despite growing like a tech start-up. The company expects meaningful margin expansion this year as it leverages its AI-powered platform across a rapidly expanding member base. The pick-and-shovel play for the AI boom Equinix (NASDAQ: EQIX) operates 260 data centers across 33 countries -- the critical infrastructure powering the AI revolution. The stock dropped 16% last Thursday after management guided for just 5% to 9% annual adjusted funds from operations (AFFO) growth -- essentially, cash flow for real estate companies -- through 2029, disappointing investors expecting AI to drive explosive expansion. But that's exactly the opportunity: Equinix must spend heavily now to build AI capacity that will pay off later. With 10,000 plus enterprises already on its platform and AI workloads requiring unprecedented interconnection, patient investors can buy this essential infrastructure play at a rare discount. The biotech with a potential blockbuster Viking Therapeutics (NASDAQ: VKTX) is developing what could be the next breakthrough obesity drug. Its dual agonist VK2735 showed up to 14.7% weight loss in just 13 weeks during phase 2 trials -- competitive with marketed GLP-1 drugs but potentially with better tolerability. With the obesity drug market expected to reach $130 billion by 2030, Viking's $3.1 billion market cap looks tiny if VK2735 succeeds. The company plans to announce Phase 2 oral data later this year, a catalyst that could drive a radical revaluation of the stock. The AI pure play trading at a discount (NYSE: BBAI) provides AI-powered analytics for defense and commercial customers, with revenue growing just 2% year over year to $158 million in 2024. The company's decision-intelligence platform helps organizations make sense of complex data in real time -- a critical capability as data volumes explode. Trading at 10.6 times trailing sales, versus 30-plus times for many high-profile AI stocks, BigBear offers exposure to practical AI applications at a reasonable valuation. Recent contract wins with the Army and Air Force validate its technology. The space company reaching escape velocity Rocket Lab (NASDAQ: RKLB) posted 32% revenue growth to $123 million in Q1 2025, with its annual revenue run rate approaching $500 million. The company completed 16 launches in 2024 and has over 20 booked for 2025. However, the real story is Neutron, its medium-lift rocket set to debut in late 2025. With a $1.45 billion federal contract win and new satellite manufacturing capabilities, Rocket Lab is transforming from a launch provider into an end-to-end space company. At a $16.2 billion market cap at the time of this writing, it's still a fraction of SpaceX's rumored valuation. The flying taxi taking off Archer Aviation (NYSE: ACHR) is progressing through FAA certification for its electric vertical takeoff aircraft. While the company targets commercial operations in Abu Dhabi as early as Q4 2025, aviation certification timelines are notoriously optimistic, and prudent investors should expect delays. Still, with over $1 billion in funding, United Airlines ordering 200 aircraft, and partnerships with Southwest and the Department of Defense, Archer has serious backing. The total addressable market for urban air mobility could reach $1 trillion by 2040 -- making today's $5.45 billion valuation potentially attractive for patient investors. The other flying taxi with the first-mover advantage Joby Aviation (NYSE: JOBY) is arguably ahead of Archer, having entered the final phase of FAA certification with Type Inspection Authorization testing. The company plans to carry its first passengers in Dubai by late 2025 or early 2026. With Toyota Motor investing $500 million and a strong $813 million cash position, Joby has the resources to reach commercialization. The company's consistent execution and manufacturing progress -- with five aircraft rolling off its production line -- demonstrates its operational maturity in the nascent eVTOL industry. The power semiconductor disruptor Navitas Semiconductor (NASDAQ: NVTS) makes gallium nitride (GaN) power semiconductors that are revolutionizing everything from electric-vehicle (EV) chargers to data center power supplies. While revenue declined 40% year over year to $14 million in Q1 2025, the company is positioned for a major inflection point with GaN production ramp ups expected in AI data centers, solar micro-inverters, and EVs over the next 12 months. With over 250 million GaN chips shipped and industry-leading reliability, Navitas offers a speculative play on the inevitable transition from silicon to next-gen power semiconductors. The lunar economy pioneer Intuitive Machines (NASDAQ: LUNR) made history in 2024 as the first commercial company to successfully land on the moon. Now, the company is executing on its vision, with Q1 2025 revenue of $62.5 million and its first-ever positive free cash flow of $13.3 million. With a $272 million contracted backlog, a strong $373 million cash position, and 2025 revenue guidance of $250 million to $300 million, the company is building the infrastructure for the emerging lunar economy. As NASA's Artemis program accelerates and commercial lunar activities expand, Intuitive Machines is positioned as the SpaceX of moon missions. The AI platform with government backing Palantir (NASDAQ: PLTR) needs no introduction, but its 2025 setup is particularly compelling. The company's AI Platform (AIP) is seeing explosive adoption, with U.S. commercial customer count growing 39% year over year, while U.S. commercial revenue surged 71%. Government revenue remains rock solid at $373 million quarterly, providing a stable base for commercial expansion. While the stock has run up significantly, Palantir's unique position bridging classified government AI and commercial applications creates a moat that's nearly impossible to replicate. The growth continues These 10 stocks share common traits. Each is attacking massive markets, hitting operational inflection points, and trading at reasonable valuations relative to potential. While the broader market obsesses over whether Nvidia is overvalued or if the AI bubble will burst, these companies are quietly building the future. Yes, many have already delivered strong returns, but the best growth stories often last longer than investors expect. With massive addressable markets and early execution proving their models work, these 10 stocks still offer compelling risk-reward for investors willing to look beyond the Magnificent Seven. Should you invest $1,000 in Oscar Health right now? Before you buy stock in Oscar Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Oscar Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $722,181!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $968,402!* Now, it's worth noting Stock Advisor 's total average return is1,069% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025 George Budwell has positions in Archer Aviation, Intuitive Machines, Joby Aviation, Navitas Semiconductor, Nvidia, Palantir Technologies, Rocket Lab, Toyota Motor, and Viking Therapeutics and has the following options: long January 2026 $55 calls on Viking Therapeutics, long January 2026 $60 calls on Viking Therapeutics, and long January 2027 $60 calls on Viking Therapeutics. The Motley Fool has positions in and recommends Equinix, Nvidia, Palantir Technologies, and Rocket Lab. The Motley Fool recommends Southwest Airlines and Viking Therapeutics. The Motley Fool has a disclosure policy.
National Post
10 minutes ago
- National Post
Predictmedix AI Expands into Mobile Diagnostics with New AI-Driven Diabetes Screening Platform
Article content TORONTO — Predictmedix AI Inc. (CSE: PMED | OTC: PMEDF | FRA: 3QP), a leader in artificial intelligence-driven health screening solutions, is expanding into the direct-to-consumer market with a mobile solution designed to deliver rapid, non-invasive diabetic screening — with India identified as the initial launchpad for this transformative initiative. Leveraging the company's proprietary AI technology, the platform is intended to empower millions with instant access to diabetic risk assessments using only a smartphone, eliminating the need for blood draws, lab visits, or clinical infrastructure. Article content By combining advanced facial and biometric analysis with seamless smartphone delivery, the solution brings accessible, affordable, and scalable diabetic screening to some of the most underserved populations across India. This milestone represents a significant step in Predictmedix AI's broader vision to reshape global healthcare delivery and accelerate the adoption of AI-enabled, mass-scale preventive health solutions. Article content 'We are addressing a critical gap in healthcare access with a cutting-edge solution that empowers individuals to take control of their health using the device they already own — their mobile phone,' said Dr. Rahul Kushwah, COO of Predictmedix AI. 'India has over 100 million diabetics and a significant number remain undiagnosed. Our app is designed to bridge that diagnostic divide.' Article content Key Features: Article content Instant Diabetic Risk Scoring via smartphone. AI-driven facial and biometric analysis based on Predictmedix's proven non-invasive screening platform. User-friendly design with multilingual support for broad accessibility. Secure, privacy-compliant data handling, in line with India's Digital Personal Data Protection (DPDP) Act. Article content Strategic Significance: Article content India's diabetes epidemic is accelerating, with estimates projecting nearly 1 in 3 adults to be diabetic or prediabetic by 2045. Simultaneously, smartphone adoption now exceeds 1.1 billion users — a convergence that creates a once-in-a-generation opportunity for mobile-first, AI-powered health solutions. Article content Our platform is uniquely positioned to: Article content Generate recurring revenue streams through direct-to-consumer and B2B channels. Article content Details of the company's recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at: About Predictmedix AI Inc. Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn. Article content Caution Regarding Forward-Looking Information: This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. Persons', as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry. Article content All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law. Article content Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. Article content Article content Article content Article content Article content Article content
CTV News
2 hours ago
- CTV News
Asian shares are mixed as Trump's tariffs deadline looms
Currency traders work near a screen showing the Korea Composite Stock Price Index (KOSPI) at the foreign exchange dealing room of the KEB Hana Bank headquarters in Seoul, South Korea, Wednesday, July 2, 2025. (AP Photo/Ahn Young-joon) MANILA, Philippines — Asian shares were trading mixed on Wednesday as the July 9 deadline for the U.S. to strike deals with trading partners or impose higher tariffs looms. U.S. futures edged higher and oil prices were little changed. Shares fell in Japan, hit by jitters over a lack of progress in trade talks with the U.S., but they recovered much of their lost ground, trading 0.5% lower at 39,790.85. Stephen Innes, managing partner at SPI Asset Management, pointed to President Donald Trump's declaration that there will be no extension of his tariff pause, which is just a week away from ending. 'The message was blunt: if Tokyo won't yield, it will pay. Tariffs of 30%, 35% or 'whatever number we determine' are now openly back on the table,' he said. 'The negotiating table just became a pressure cooker.' Hong Kong's Hang Seng advanced 0.8% to 24,271.15 and the Shanghai Composite index edged 0.1% lower to 3,453.89. South Korea's KOSPI fell 0.6% to 3,072.63 after the government reported that inflation rose in June. Australia's S&P ASX 200 climbed 0.8% to 8,605.40. Taiwan's Taiex edged up 0.1% while the Sensex in India lost 0.2%. On Tuesday, the S&P 500 dipped 0.1% to 6,198.01 for its first loss in four days. The Dow Jones Industrial Average rose 0.9% to 44,494.94, and the Nasdaq composite fell 0.8% to 20,202.89. Tesla tugged on the market as the relationship between its CEO, Elon Musk, and President Donald Trump soured even further. Once allies, the two have clashed recently, and Trump suggested there's potentially 'BIG MONEY TO BE SAVED' by scrutinizing subsidies, contracts or other government spending going to Musk's companies. Tesla fell 5.3%. It has lost just over a quarter of its value so far this year, 25.5%, in large part because of Musk's and Trump's feud. Drops for several darlings of the artificial-intelligence frenzy also weighed on the market. Nvidia's decline of 3% was the heaviest weight on the S&P 500. But more stocks within the index rose than fell, led by several casino companies. They rallied following a report showing better-than-expected growth in overall gaming revenue in Macao, China's casino hub. Las Vegas Sands gained 8.9%, Wynn Resorts climbed 8.8% and MGM Resorts International rose 7.3%. Automakers outside of Tesla were also strong, with General Motors up 5.7% and Ford Motor up 4.6%. The U.S. stock market has made a stunning recovery from its springtime sell-off of roughly 20%. But challenges still lie ahead for Wall Street, with one of the largest being the continued threat of Trump's tariffs. Many of Trump's stiff proposed taxes on imports are currently on pause, and they're scheduled to kick into effect in about a week. Depending on how big they are, they could hurt the economy and worsen inflation. Washington is also making progress on proposed cuts to tax rates and other measures that could send the U.S. government's debt spiraling higher, which could raise inflation. That in turn could mean higher interest rates, which would hurt prices for bonds, stocks and other investments. Despite such challenges, strategists at Barclays say they see signals of euphoria among some investors. The strategists say a measure that tries to show how much 'excess optimism' is in the market is not far from the peaks seen during the 'meme stock' craze that sent GameStop to market-bending heights or to the dot-com bubble at the turn of the millennium. In other dealings early Wednesday, benchmark U.S. crude lost 8 cents to $65.37 per barrel. Brent crude, the international standard, lost 3 cents to $67.08 per barrel. The U.S. dollar rose to 143.70 Japanese yen from 143.41 yen. The euro slid to $1.1787 from $1.1808. Teresa Cerojano, The Associated Press
